Integrated Investment Consultants LLC Has $1.87 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

Integrated Investment Consultants LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 1.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,118 shares of the company’s stock after acquiring an additional 283 shares during the period. Integrated Investment Consultants LLC’s holdings in Merck & Co., Inc. were worth $1,866,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Ruedi Wealth Management Inc. grew its holdings in Merck & Co., Inc. by 180.2% in the third quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the period. AlphaMark Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $34,000. Valued Wealth Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $42,000. TFO Wealth Partners LLC boosted its holdings in Merck & Co., Inc. by 108.1% during the third quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock worth $48,000 after purchasing an additional 241 shares during the last quarter. Finally, Ameliora Wealth Management Ltd. purchased a new position in Merck & Co., Inc. during the third quarter worth about $50,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Buying and Selling

In related news, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares in the company, valued at $2,443,972.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the transaction, the insider now directly owns 19,569 shares in the company, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Merck & Co., Inc. Stock Up 0.6 %

MRK stock traded up $0.73 during trading on Wednesday, hitting $131.08. 418,716 shares of the stock traded hands, compared to its average volume of 8,582,164. Merck & Co., Inc. has a 1 year low of $99.14 and a 1 year high of $133.10. The firm’s 50 day moving average is $125.45 and its two-hundred day moving average is $113.20. The stock has a market cap of $331.98 billion, a price-to-earnings ratio of 931.07, a price-to-earnings-growth ratio of 0.52 and a beta of 0.38. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. The firm had revenue of $14.63 billion for the quarter, compared to the consensus estimate of $14.49 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.62 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 8.59 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.35%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s payout ratio is presently 2,200.00%.

Analyst Ratings Changes

Several analysts have commented on MRK shares. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective for the company. in a research note on Monday, March 11th. Truist Financial reaffirmed a “buy” rating and set a $142.00 price objective (up previously from $139.00) on shares of Merck & Co., Inc. in a research note on Thursday, March 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, March 27th. Finally, TD Cowen raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus target price of $129.71.

Read Our Latest Stock Report on Merck & Co., Inc.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.